Title : Economic evaluation of agomelatine relative to other antidepressants for treatment of major depressive disorders in Greece.

Pub. Date : 2013 May 10

PMID : 23663281






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 RESULTS: Base case analyses revealed that agomelatine is a dominant therapy for MDD relative to escitalopram, fluoxetine and sertraline, and it appeared to be cost-effective compared to venlafaxine (ICER: $547/QALY). agomelatine cAMP responsive element modulator Homo sapiens